CN1514706A - Therapeutic film forming composition and treatment system - Google Patents
Therapeutic film forming composition and treatment system Download PDFInfo
- Publication number
- CN1514706A CN1514706A CNA028035100A CN02803510A CN1514706A CN 1514706 A CN1514706 A CN 1514706A CN A028035100 A CNA028035100 A CN A028035100A CN 02803510 A CN02803510 A CN 02803510A CN 1514706 A CN1514706 A CN 1514706A
- Authority
- CN
- China
- Prior art keywords
- definition
- therapy system
- weight
- volume
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 19
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
- 230000037317 transdermal delivery Effects 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 42
- 239000000463 material Substances 0.000 claims description 41
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000012423 maintenance Methods 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 11
- -1 polyethylene Polymers 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 229920002678 cellulose Chemical class 0.000 claims description 9
- 239000001913 cellulose Chemical class 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 235000013877 carbamide Nutrition 0.000 claims description 8
- 239000012744 reinforcing agent Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000002955 immunomodulating agent Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 230000002584 immunomodulator Effects 0.000 claims description 6
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 6
- 239000011118 polyvinyl acetate Substances 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 229940124091 Keratolytic Drugs 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000002141 anti-parasite Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 230000001530 keratinolytic effect Effects 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 3
- 229920002160 Celluloid Polymers 0.000 claims description 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Chemical class 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- 229940081735 acetylcellulose Drugs 0.000 claims description 3
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004063 butyryl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229940025250 camphora Drugs 0.000 claims description 3
- 239000010238 camphora Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 229960002311 dithranol Drugs 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 239000003410 keratolytic agent Substances 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 229940049964 oleate Drugs 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 229920002451 polyvinyl alcohol Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000011269 tar Substances 0.000 claims description 3
- 229920001169 thermoplastic Polymers 0.000 claims description 3
- 239000004416 thermosoftening plastic Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 229920000181 Ethylene propylene rubber Polymers 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 2
- 229960003338 crotamiton Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 2
- 229960005426 doxepin Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000490 permethrin Drugs 0.000 claims description 2
- 229920001083 polybutene Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229960001807 prilocaine Drugs 0.000 claims description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 2
- 239000013013 elastic material Substances 0.000 claims 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 1
- 229920006387 Vinylite Polymers 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 210000001513 elbow Anatomy 0.000 claims 1
- 210000002683 foot Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 abstract description 14
- 208000000260 Warts Diseases 0.000 abstract description 7
- 201000010153 skin papilloma Diseases 0.000 abstract description 7
- 230000035515 penetration Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 208000004554 Leishmaniasis Diseases 0.000 abstract description 3
- 201000005708 Granuloma Annulare Diseases 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 210000004905 finger nail Anatomy 0.000 description 71
- 210000003491 skin Anatomy 0.000 description 29
- 238000000034 method Methods 0.000 description 10
- 210000000282 nail Anatomy 0.000 description 9
- 239000010408 film Substances 0.000 description 6
- 208000026721 nail disease Diseases 0.000 description 6
- 229920000832 Cutin Polymers 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000006187 Onycholysis Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920002725 thermoplastic elastomer Polymers 0.000 description 4
- 210000004906 toe nail Anatomy 0.000 description 4
- 206010041663 Splinter haemorrhages Diseases 0.000 description 3
- 241001247821 Ziziphus Species 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000197194 Bulla Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001517488 Clavus Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010053177 Epidermolysis Diseases 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 206010018381 Glomus tumour Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 206010028698 Nail dystrophy Diseases 0.000 description 2
- 206010048886 Onychoclasis Diseases 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N alpha-methacrylic acid Natural products CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000017338 epidermoid cysts Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 201000010192 nonsyndromic congenital nail disorder 1 Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000008743 palmoplantar keratosis Diseases 0.000 description 2
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000011068 Bazex syndrome Diseases 0.000 description 1
- 208000034068 Bazex-Dupré-Christol syndrome Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 208000010305 Epidermal Cyst Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 206010022013 Ingrowing nail Diseases 0.000 description 1
- 208000002078 Ingrown Nails Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 208000001913 Lamellar ichthyosis Diseases 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 206010058455 Nail pigmentation Diseases 0.000 description 1
- 206010030336 Onychogryphosis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001052 Pachyonychia Congenita Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000009163 Sebaceous of Jadassohn Nevus Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000596 acrodermatitis enteropathica Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000009356 dyskeratosis congenita Diseases 0.000 description 1
- 208000002169 ectodermal dysplasia Diseases 0.000 description 1
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- KSOKAHYVTMZFBJ-UHFFFAOYSA-N iron;methane Chemical compound C.[Fe].[Fe].[Fe] KSOKAHYVTMZFBJ-UHFFFAOYSA-N 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000011856 onychomatricoma Diseases 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000003619 porokeratosis Diseases 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002025 wood fiber Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
A film forming composition incorporating one or more therapeutic substances for application to nails and/or skin surfaces which can be employed independently or, if desired, in combination with an easily employed holding or support member for delivering heat directly to the application site for treating nails and/or skin surfaces for a wide variety of medical problems is disclosed. The disclosed treatment system for providing an effective transdermal delivery of therapeutic agents possesses broad applicability for a wide range of medical conditions, including the numerous diseases, disorders, and medical problems, all of which are capable of being treated using this treatment system. In particular, diseases, disorders, and medical conditions which include, but are not limited to, psoriasis, skin cancers, warts, leishmaniasis, mycobacteria, and granuloma annulare can be specifically treated under controlled conditions due to the efficacy of heat penetration in treating these disorders.
Description
Technical field
The present invention relates to fingernail, toenail the inside and disease following and that skin surface is found, relate more specifically to be used for rem is delivered to the fully-integrated therapy system of the disease that influences fingernail and skin surface.
Background technology
The skin surface that influence is individual and/or the disease right and wrong of fingernail and/or toenail are usually seen, and are often brought practical difficulty to diseased individuals.Describe in detail as this paper, found that a large amount of diseases torments individuality by this way, and fail to obtain actual effectively medicine.
In order to be familiar with the difficulty that runs in this field, it is important understanding the fingernail particular structure.Known fingernail is the cutin adnexa by the uniqueness of the stratum germinativum epithelium generation of basic unit.The similar of typical fingernail is in the structure of skin surface, and wherein the base table chrotoplast produces horny layer.But fingernail has the cutin harder than skin owing to having higher sulfenyl layer albumen.
Fingernail is not grown by adding from the cell of basic unit with stopping.The unitary epithelium component of fingernail comprises the proximal nail fold that is similar to skin or slight sour jujube skin shape, and comprises the granulosa with mitogen activation.The end products of cutin is an epidermis.Basic unit is sour jujube skin shape and does not contain the granulosa with minimum mitogen activation.The cutin end products is the deck.Nail matrix is very flat and do not contain the granulosa with minimum mitogen activation, and on the deck when far-end moves only the minority horn cell be added to below the deck.At last, nail matrix is sour jujube skin shape, contains the granulosa with mitogen activation, and similarly is only to have the minority horn cell to be added to the lower floor on far-end deck with epidermis.
Fingernail and disease of nail are being carried out may or running into a large amount of problems below the nail surface at fingernail itself in the therapeutic process.In order to fully understand the importance of this problem, provide following table may experience and need the effectively representative sample inventory of disease, disease and the medical problem of treatment as multiple:
Table A
Influence the dermatosis of fingernail
Psoriasis/pustular psoriasis
Lichen planus
The congenital atrophy of fingernail
The glossiness lichen
Lichen striatus
Struvite linear verrucous epidermal nevus
Alopecia areata
Twenty-nail dystrophy (coarse onychitis)
The eczema of involving fingernail
The Pornpholyx that involves fingernail
Parakeratosis pustulosa (Parakeratosis pustalosa)
Pemphigus
Bullous pemphigoid
Acquired bulla type epidermolysis
The erythema multiforme of involving fingernail
Darier's disease
Pityriasis rubra pilaris
Palmoplantar keratoderma
The Bazex syndrome
Table B
Fingernail in the general disease is got involved
Onycholysis as the 3rd common disease of nail in the dermatological after tinea unguium and wart.
Fingernail pigmentation (Chromonychia)
Hemorrhage
Piptonychia (onycholysis or spontaneous loss of finger-nail fully)
Hapalonychia (soft fingernail)
Onychorrhexis (old, old fingernail)
Coarse first
Table C
The fingernail tumor
The epidermis tumor
Optimum
Clavus under the fingernail
Wart
Cyst (epidermis inclusion/epidermoid cyst)
Onychomatricoma
Melanocytoma
Glomus tumor
Mucocele
Purulent granuloma
Pernicious
Bowen's disease/squamous cell carcinoma
Malignant melanoma
Cutaneous tumor
Optimum
Fibroma
Hemangioma
Glomus tumor
Purulent granuloma
Splinter hemorrhage
Tumor under the fingernail
Exostosis under the fingernail
Hematoma under the fingernail
The coloring disease
Hypopigmentation/increase disease/melanonychia
Infect
Fungal infection (dermatophytes, yeast, deep layer fungus)
Bacterial infection (Gram-positive, gram negative bacteria etc.)
Viral infection (herpes simplex, wart etc.)
Other infection (anonymous mycobacteria, sporotrichin, leishmaniasis etc.)
Mixed infection (paronychia)
Table D
CDK
Da-Huai disease
Pachyonychia congenita
Congenital onychodysplasia
Bulla type epidermolysis
Twenty-nail dystrophy
Pityriasis rubra pilaris
Lamellar ichthyosis
Epidermolytic hyperkeratosis
Porokeratosis
Palmoplantar keratoderma
The periodicity of fingernail comes off
Ectodermal dysplasia
Luo-Tang syndrome
Dyskeratosis congenita
Acrodermatitis enteropathica
The Goldtz syndrome
The Kid syndrome
Table E
Fingernail changes/with aging diseases associated
Change
Variable color
Profile/shape
Surface abnormalities
Thickness
The linear growth that reduces
Disease
Crisp fingernail
Onychodystrophy-exogen
Onychauxis
Onychoclasis (clavus under the fingernail)
Ingrowing nail (ingrown nail)
Onychogryphosis
Splinter hemorrhage
Hematoma under the fingernail
Nail infection
Finding to be proved to be an individual extremely difficult field that obtains effectively treatment is psoriasis, particularly relevant with fingernail or toenail psoriasis treatment.The U.S. has more than 6,400,000 psoriasis cases according to estimates, influences the common American population of about 2%-3%.According to national psoriasis foundation, annual diagnosis about 200,000 routine new cases, and to cause annual total outpatient's cost be $160 ten thousand-$320 ten thousand.And annual according to estimates psoriatic loses about 5,600 ten thousand hours work.
The psoriasis of fingernail is very common, and is finding among all patients of 50% at the most.As if than toenail susceptible to more, this brings additional problem to fingernail, changes because the patient more may complain the fingernail of being seen easily.The result is, the influence of psoriasis fingernail disease is on the health also to be psychological.
The psoriasic clinical symptoms of fingernail depends on the unitary anatomy of the fingernail that involves position.These defectives alter a great deal, and comprise one or more fingernails depression, variable color, thicken and onycholysis (separating) from nail matrix.The effect of onycholysis also may relate to the similarly basic fingernail of tinea unguium under structure.Other is common is changed to division, Beau lines (the generally horizontal wrinkle in deck that is caused by intermittent basic unit psoriasis), the splinter hemorrhage on deck malnutrition, rice scholar's line (the horizontal white line on deck), Muehrcke line (because horizontal white line that the abnormal vascular pattern in the visible nail matrix causes in the whole deck), deck and refers to subungual hyperkeratosis.
The purpose of treatment psoriasis fingernail disease is to improve the health relevant with onychodystrophy and psychological weak.Unfortunately, the treatment of using at present can not be cured the psoriasis fingernail.Though multiple trial and Therapeutic Method are arranged in the prior art at present, do not have specific, consistent, the effective treatment of treatment fingernail psoriasis.
Used several different methods, comprised in part, the disease location and whole body method, radiotherapy etc.But most of these prior art Therapeutic Method have actual risk and complication, comprise general toxicity, radiation infectious-related complication, skin atrophy on every side, pain etc.In addition, advised that nail varuish is used for many prior art preparations treats psoriasis to be applied to fingernail, and many other fingernail diseases.
But it is invalid that the nail varuish of these prior aries also proves in the solution of the disease of nail that they are intended to treat.The result is, constantly need have the therapy system of a kind of safe and effective fingernail and disease of nail for a long time, finds satisfied scheme before use easily, safety and the effective the present invention of cost.
Therefore, a basic purpose of the present invention provides a kind of people's of being used for therapy system, and this system can make things convenient for and easily be applied to any target surface of people, comprises nail surface and skin surface, provide the rapid draing thin film, and the combining target therapeutic agent is to handle multiple medical problem.
Another object of the present invention provides a kind of therapy system efficiently, it is characterized in that the feature of above detailed description, and it also uses thermal gradient sending with further enhancing therapeutic agent.
Another object of the present invention provides the effective therapy system of a kind of height, and this system has the feature of above detailed description, and can be easily and be used for the treatment of a large amount of medical symptoms effectively.
Another object of the present invention provides a kind of therapy system efficiently, and this system has the feature of above detailed description, and also cooperate in conjunction with the maintenance that makes up and supporting element or with film-forming composition and heat production element and use easily and use guaranteeing.
Other and more specific purpose are that part is conspicuous, and will appear at hereinafter part.
Detailed Description Of The Invention
By using the present invention, eliminate all obstacles and the defective found in prior art compositions, system, method and the step, and obtain a kind of part, effective therapy system of using, making things convenient for, satisfy the needs of consumers, be used for a lot of medical problems of fingernail and/or skin surface.Obtain a kind of therapy system among the present invention, this therapy system comprises the film-forming composition that is applied to the therapeutant of fingernail and/or skin surface in conjunction with one or more, it can use separately, perhaps is used in combination with easy-to-use support or the carrier element that is used for heat directly is delivered to application site if necessary.
Therapy system of the present invention has the broad applicability that is used for a large amount of medical symptoms.Particularly, use the present invention can treat multiple disease, disease and the medical problem of above detailed description.Particularly, because effectiveness of the present invention and in use treatment in these diseases thermal break-through effectiveness and disease, disease, the medical symptom that can specifically treat or improve include but not limited to psoriasis, skin carcinoma, wart, leishmaniasis, mycobacterial diseases and granuloma annulare.
In this respect, the application of determining heat slows down, suppresses or reverses metabolic process, immunologic process or biological symptom or rely on process hot or that be influenced by heat.The result is, according to the embodiment of the present invention that comprise integrated therapy system, by being used in combination the treatment that this paper describes in detail with thermal source or containing the medicine film-forming composition and treat multiple medical symptom effectively.
Found that the use of heat produces positive, collaborative effect to the targeting of the medicine of predetermined quantity and/or penetration enhancers, controlled sending.In this respect, the application of the invention improvement or effective treatment are used for above disease of nail, disease and medical symptom and/or the medicine of skin and subcutaneous surface and/or the topical application of penetration enhancers that intactly describes in detail.And, medicine and/or penetration enhancers are delivered to fingernail, or by fingernail be delivered to basic organization with realize need not be oral and/or need not be parenteral, system, transdermal delivery, this method itself is effectively and further to be enhanced in the presence of controlled thermal gradient.
Usually, it is relevant with the basic organization of being correlated with fingernail therapy system of the present invention and fingernail below to be described in detail in detail.But, the present invention be equally applicable to find at skin surface with the incoherent disease of fingernail, disease and medical problem.Therefore, should be appreciated that the present invention and content provided herein are equally applicable to use at any skin surface.Therefore, being provided at using in detail and using on the fingernail only is the purpose that exemplifies, and in fact the invention is intended to be included in application and use on fingernail and the skin surface.
A solvent of the present invention is a kind of film-forming composition that is used for one or more therapeutants are delivered to its application site of formulated.This film-forming composition can be used for anyone surface, but it is used in particular for fingernail to treat any target disease of nail.
Except comprising one or more therapeutants, film-forming composition of the present invention also preferably comprises film former, plasticizer and carbamide, and all these is in the volatile vehicle.With reference to table 1, the dosage range of every kind of composition is very clearly.This table provides total usable range and preferable range.
Table I
| Composition | Total size (%w/v) | Preferable range (%w/v) |
| Film former | ????0.5-25 | ????5-10 |
| Plasticizer | ????0.5-25 | ????1-5 |
| Carbamide | ????0.5-20 | ????1-6 |
| Therapeutant | Required effective dose | Required effective dose |
| Solvent/volatile vehicle | ????40-90 | ????50-80 |
In preparation of compositions of the present invention, can use any required film former.But, in preferred compositions, film former comprises at least a following material that is selected from: mixed polymer, polyvinyl acetate, polyethylene butyryl, polyvinyl alcohol, cellulose derivative such as the acetic acid of polyvinyl acetate, vinyl acetate and acrylic acid polymerization of mixtures thing, (methyl) acrylic acid and (methyl) acrylate gathers O-phthalic acid cellulose, cellulose acetate-butyrate, cellulose-acetate propionate, celluloid, sulfate cellulose, ethyl cellulose and cellulose acetate.In this respect, a kind of preferred film former is aminomethyl acrylate copolymer (II), and this material is by Rohm Pharma GmbH, Weiterstadt, and Germany sells, and trade mark is called " Eudragit RL-100 ".
In addition, can in objective composition, use any target plasticizer, in a preferred composition, this plasticizer composition comprises at least a following material that is selected from: glyceryl triacetate, polyhydric alcohol such as propylene glycol and butanediol, Oleum Ricini, Camphora and phthalic acid ester.In this respect, preferred plasticizer comprises dibutyl phthalate, and this material is sold by Eastman Chemicals, and trade mark is called " Eastman DBT Plasticizer ".
In preparation of compositions of the present invention, can use any The suitable solvent or volatile vehicle.But, found that solvent/volatile vehicle preferably comprises one or more and is selected from following material: alcohol (as ethanol), ketone (as acetone), ether (as chloroform), aromatic hydrocarbons (as toluene), ester (as ethyl acetate) and water.
In the combination of selecting and preparing the composition that is used for solvent/volatile vehicle, found that preferred chemical compound or chemical compound should be as the solvents of carrier, and have such evaporation rate: slowly to being enough to that active component is applied to fingernail or skin surface fully, and soon to preventing that wiping falls under the situation that compositions comes in contact on fingernail or skin surface and another surface.
The preferred prescription such as the Table II that are used for this treatment film-forming composition describe in detail.In the preparation of this preferred compositions, at first with film former, promptly Eudragit RL-100 is dissolved in acetone/water carrier.After forming settled solution, add other composition and be mixed to dissolving fully mutually with it.In addition, also add goal treatment agent and the mutual goal treatment film-forming composition that is applied to fingernail or skin with formation that mixes.
Table II
| Composition | Quantity |
| Clobetasol propionate | ????0.05％w/v |
| Carbamide | ????3％w/v |
| Dibutyl phthalate | ????1.5％w/v |
| ????Eudragit?RL-100 | ????7％w/v |
| Ethanol | ????70％w/v |
| Water | In right amount to 100% |
In the finishing of treatment film-forming composition of the present invention, will be enough to provide one or more therapeutants of the quantity of interacting goals to be added to said composition.Usually, the therapeutant of use comprises that one or more are selected from following material: corticosteroid, chemotherapeutant, anesthetis, hydryllin, antibacterial, antiparasitic, antiviral agent, antioxidant, tar, dithranol, immunomodulator, keratolytic and antitumor agent.Though a large amount of chemical products is within the scope of these medicines, following inventory provides the exemplary composition that effectiveness is made the part of therapy system of the present invention.But, provide this inventory only to be used to the purpose that exemplifies, and be not intended to restriction the present invention.
In this respect, corticosteroid can comprise that one or more are selected from following material: hydrocortisone, triamcinolone, betamethasone and any other steroid commonly used in the topical application of skin; Chemotherapeutant can comprise that one or more are selected from following material: 5FU, bleomycin, methotrexate, cytotoxicity medicine; Anesthetis can comprise that one or more are selected from following material: lignocaine, prilocaine and Pramoxine; Hydryllin can comprise that one or more are selected from the material of diphenhydramine and salt or doxepin; Antibacterial can comprise that one or more are selected from following material: gentamycin, tetracycline, erythromycin and Clindamicin, amoxicillin; Antiparasitic can comprise that one or more are selected from following material: metronidazole, Permethrin and crotamiton; Antiviral agent can comprise that one or more are selected from the material of acycloguanosine; Antioxidant can comprise that one or more are selected from the material of ascorbic acid and tocopherol; Immunomodulator can comprise that one or more are selected from the material of imiquimod and beta glucan; Keratolytic can comprise that one or more are selected from salicylic material; And antitumor agent can comprise that one or more are selected from the material of cytotoxicity medicine and immunomodulator.
And, describe in detail as this paper, found that the use of the thermal gradient that provided by a selectable embodiment of the present invention makes reinforcing agent more effectively use effectively.In this respect, as following abundant detailed description, the reinforcing agent of specifically benefiting from this embodiment of the present invention comprises that one or more are selected from following material: solvent, surfactant, ether, ester, fatty glyceride, carbamide, oleate, liposome, biostearin and closing compound.
As discussed above, the present invention includes the treatment film-forming composition is used separately in one embodiment, also comprise and use the hot delivery elements that is used in combination with the treatment film-forming composition.Use when of the present invention at fingernail and/or skin surface, will treat film-forming composition and be applied to fingernail and/or skin surface.When using this embodiment, in case form thin layer, hot delivery elements is placed on the fingernail so that the direct successive thermal gradient that influences fingernail and/or skin surface to be provided.
As above-mentioned, found that the application of heat strengthens sending and rendeing a service of many therapeutants.When using this embodiment, preferably send by using the heat that makes up with holding element to send liner realization heat.In preferred construction, heat release liner or hot delivery patch are as thermal source.Heat release liner or hot delivery patch be developed in the past and generally comprised contain in the presence of oxygen, will take place exothermic reaction with produce heat chemical substance porous membrane or spin cloth or the liner of nonwoven cloth material.
Though can use any desired chemical substance, heat release liner or hot delivery patch generally comprise the mixture of moxa or iron powder, activated carbon, the wood fiber, water and salt.Selectively, the mixture that uses alkaline sulfides and cementite and chemical substance and storage contact with oxygen before the use preventing.In addition, the big or small sufficient to guarantee of spacer holes is realized target air flow.If necessary, can use any heat production liner, product or structure.
Using tiles/mats to be enclosed in as last does not have in the pouch smell and to form in noble gas such as nitrogen.As long as tiles/mats remains in the hermetic container before use, just chemical reaction can not take place.But, in case this pouch is opened the then exothermic reaction that the existence of oxygen causes chemical reaction and takes place to expect in the air.
In embodiments of the invention, by allowing user that liner or patch are used heat release liner or hot delivery patch individually at thermal therapeutical targeting desired area.If necessary, by relevant bonder hot delivery patch or heat release liner are remained on target site separately safely.
In case liner/paster safety remain on accurate target location, the holding element of therapy system of the present invention is fixed on the target location, make add heating pad or heat release paster periphery around or remain on the target location safely, help to regulate and control heat level and the air that arrives heat release liner or hot delivery patch transmit.By this method, that realize ideal, controlled heat is sent or thermal gradient, can treat a large amount of medical symptoms effectively.Except the controlled thermal that is provided for directly treating some medical symptom is sent, it is effectively that the thermal gradient that provides in the embodiment of fully-integrated therapy system of the present invention is provided, and improves the penetrance of bonded whole body and topical medications in the treatment film-forming composition.
Can obviously find out from above-mentioned, use therapy system of the present invention to treat a large amount of multiclass medical symptoms effectively and effectively.As described in detail above, this has an embodiment of therapy system to introduce hot delivery patch or the heat release liner that makes up with holding element, and this holding element is with hot delivery patch or the heat release liner remains on the specific medical problem of appearance and expectation heat is sent or the accurate target position of thermal gradient.In addition, fingernail or skin penetration reinforcing agent can be integrated into therapy system of the present invention with its effectiveness of further enhancing.
Field by the application heat that lot of documents is put down in writing is the treatment of wart.In this respect, 5,053,024 full disclosure of Dvoretzkv United States Patent (USP) the thermal therapeutical of wart.But it generally is unknown using heat and use heat for the transmission that helps medicine and fingernail/skin penetration reinforcing agent and absorption in other skin disorder or medical problem, and represents the progress in present technique field, especially with the combination for the treatment of film-forming composition.
This embodiment of the application of the invention therapy system, comprise treatment film-forming composition with holding element and hot delivery patch or the combination of heat release liner, the temperature of fingernail or skin raises or remains on about 39-45 ℃, and the time range that continues is about 1-10 hour; The application of the invention, the heat level of fingernail or contact skin remains on little and controlled scope, and this representative is used for the treatment of the optimal heat contact of medical symptom and accurately sends drug target.The result realizes best performance and treatment.
According to the present invention, the supporting element specific design is used for fast and easily being installed in the part of human body as finger, with the fingernail peripheral ring of treatment around in conjunction with and the connection and remain on accurate destination locations of cooperate with film-forming composition and hot delivery patch or heat release liner.And, supporting element of the present invention is also specifically constructed by the material that is designed for especially with hot delivery patch or the cooperation of heat release liner especially, so that its cooperative interaction, thereby guarantee to keep accurate temperature required level and in the object time of smart phase, realize best oxygen flow.
The structure construction of can plurality of optional selecting forms the supporting element of maintenance of the present invention system, to provide desirable, to be directly installed on any finger or toe fast, easily, safely, maybe may need any human body anatomic part for the treatment of.In this respect, an embodiment of maintenance of the present invention system comprise one continuously, columniform tube elements basically.
By using cylindrical elements, maintenance of the present invention system can easily be installed on user's the hands or foot, and peripheral ring is around in fingernail to be treated, keeps safely, and cooperates with the heat release liner or the hot delivery patch of the pre-installation that is in the precision target position.
Feature of the present invention is the material that is used to form therapy system of the present invention.In this respect, most weaving and non-woven material can be used in the formation holding element.
But, found that preferable material comprises complete elastomer or the elastomer that wherein forms, easy installation to be provided and the maintainer line blanket insurance to be held in the pliability of appropriate location.In a preferred construction, this elastomer integral body is formed the part of this material, as thermoplastic elastomer (TPE).In this respect, preferred thermoplastic comprises and is selected from following foamed thermoplastic elastomer: polyurethane, polyolefin, polybutene, polyethylene, polyester, ethylene-propylene rubber, polypropylene, silicone and based on the resin of vinyl.
By using foamed thermoplastic elastomer, obtain the accurate target combination of closed cell and open cell, wherein the ratio of closed cell and open cell is controlled in the preferred range.By this method accurately the hot retentivity of control material and/or insulating properties and make material will from around, oxygen in the surrounding air is directly delivered to the position of hot delivery patch or heat release liner.
According to embodiment of the present invention of using heat to send, the insulation that the temperature that directly is delivered to fingernail or skin by heat release liner or hot delivery patch is provided by this maintenance system and accurately in the preset time length inner control in narrow scope.In addition, oxygen cycles through the maintenance system continuously so that the proper operation of heat release liner/paster to be provided, and air circulation is offered the surface of the fingernail or the skin of treatment.
Must see purpose that effective realization is above-mentioned and other purpose of obviously finding out by above description,, in described product and in described structure, do some modification and do not deviate from scope of the present invention because can state on the implementation in the process of method.The application is intended to the implication that will should be interpreted as exemplifying at all contained themes of above-mentioned description and not limit.
Will also be understood that following claim is intended to cover general and specific feature of the present invention as herein described, and all statements as the protection domain of the present invention of language content should drop on wherein.
Be appreciated that especially under the situation that its implication allows, in this claim, the compatible blend that is intended to comprise these compositions with the composition or the chemical compound of odd number citation.
After describing our invention, what we will look for novelty with expectation by the content that patent guarantees is:
Claims (29)
- A location that is used to provide the transdermal delivery of goal treatment agent, be applied topically to people's film forming therapeutic combination, described compositions comprisesA. weight/volume accounts for the film former of 0.5%-25% of the weight/volume of whole compositions greatly;B. weight/volume accounts for the plasticizer of 0.5%-25% of the weight/volume of whole compositions greatly;C. weight/volume accounts for the carbamide of 0.5%-20% of the weight/volume of whole compositions greatly;D. weight/volume accounts for the solvent/volatile vehicle of 40%-90% of the weight/volume of whole compositions greatly; WithE. at least a therapeutant of effective dose;Obtain a kind of any target area of individuality that can be applied to thus to provide to concrete, the location of special disease, the film forming therapeutic combination of topical therapeutic.
- 2. the therapeutic combination of claim 1 definition, wherein this film former also is defined as to comprise and is selected from following material: the mixed polymer of polyvinyl acetate, vinyl acetate and acrylic acid mixed polymer, acrylic acid and acrylate, polyvinyl acetate, polyethylene butyryl, polyvinyl alcohol, cellulose derivative, the poly-O-phthalic acid cellulose of acetic acid, cellulose acetate-butyrate, cellulose-acetate propionate, celluloid, sulfate cellulose, ethyl cellulose and cellulose acetate.
- 3. the therapeutic combination of claim 1 definition, wherein this film former also is defined as and comprises the aminomethyl acrylate copolymer.
- 4. the therapeutic combination of claim 1 definition, wherein this plasticizer also is defined as and comprises at least a following material that is selected from: glyceryl triacetate, polyhydric alcohol, propylene glycol, butanediol, Oleum Ricini, Camphora and phthalic acid ester.
- 5. the therapeutic combination of claim 4 definition, wherein this plasticizer also is defined as and comprises dibutyl phthalate.
- 6. the therapeutic combination of claim 1 definition, wherein this solvent/volatile vehicle comprises at least a following material that is selected from: alcohol, ethanol, ketone, acetone ether, chloroform, aromatic hydrocarbons, toluene, ester, ethyl acetate and water.
- 7. the therapeutic combination of claim 1 definition, wherein this solvent/volatile vehicle comprises that permission is applied to the active component of said composition the evaporation rate of wiping when skin prevents also that simultaneously compositions from coming in contact with another surface on the treatment surface fully.
- 8. the therapeutic combination of claim 7 definition, wherein this solvent/volatile vehicle also is defined as the acetone that comprises with blended 50% weight/volume of the ethanol of 50% weight/volume.
- 9. the therapeutic combination of claim 1 definition, wherein this therapeutic agent comprises one or more and is selected from following material: corticosteroid, chemotherapeutant, anesthetis, hydryllin, antibacterial, antiparasitic, antiviral agent, antioxidant, tar, dithranol, immunomodulator, keratolytic and antitumor agent.
- 10. the therapeutic combination of claim 9 definition, wherein this therapeutic agent also is defined as and comprises one or more and be selected from following material: hydrocortisone, triamcinolone, betamethasone, 5FU, bleomycin, methotrexate, cytotoxicity medicine, lignocaine, prilocaine, diphenhydramine and salt thereof, doxepin, gentamycin, tetracycline, erythromycin, Clindamicin, metronidazole, Permethrin, crotamiton, acycloguanosine, ascorbic acid, tocopherol, imiquimod, p-glucosan, salicylic acid, cytotoxicity medicine and immunomodulator.
- 11. the therapeutic combination of claim 1 definition, wherein said composition also comprises a kind of reinforcing agent that helps the delivery treatments material.
- 12. the therapeutic combination of claim 11 definition, wherein said composition also is defined as to comprise to make up and is used for cooperating, cover joint to be provided for using and sending the hot delivery apparatus of the thermal gradient of this therapeutic combination with it.
- 13. the therapeutic combination of claim 12 definition, wherein this reinforcing agent comprises one or more and is selected from following material: solvent, surfactant, ether, ester, fatty glyceride, carbamide, oleate, liposome, biostearin and closing compound.
- 14. one kind is used for the effective transdermal delivery the pure man of therapeutic agent to treat the therapy system of a large amount of medical symptoms, this system comprises:A. film-forming composition, said composition comprises:1). weight/volume accounts for the film former of 0.5%-25% of the weight/volume of whole compositions greatly;2). weight/volume accounts for the plasticizer of 0.5%-25% of the weight/volume of whole compositions greatly;3). weight/volume accounts for the carbamide of 0.5%-20% of the weight/volume of whole compositions greatly;4). weight/volume accounts for the solvent/volatile vehicle of 40%-90% of the weight/volume of whole compositions greatly; With5). at least a therapeutant of effective dose;B. heat production liner, this heat production liner in conjunction with wherein comprise and be fabricated and be used for sending when the activation heat production device of the heat of target level; WithC. one kind keeps and supporting element, and this element is fabricated and is used for1). cooperate with the heat production liner and heat can be directly applied to the intended application position of film-forming composition; With2). remain on the part of human body surface safely, engage with hot delivery patch/liner and film-forming composition cover type;Realize a kind of any target part that can remain on human body safely thus, thereby the therapy system of therapeutic agent and heat is provided for any target site in the mode of accurate control.
- 15. the therapy system of claim 14 definition, wherein supporting element is fabricated to be used for being installed to safely and is selected from a following human body parts: finger, arm, elbow, toe, foot, lower limb, wrist, ankle and upper torso.
- 16. the therapy system of claim 14 definition, wherein this maintenance and supporting element comprise one make elongation that this element remains on any target location safely, planar structure in conjunction with fixture basically.
- 17. the therapy system of claim 16 definition, wherein this fixture is defined as and comprises a kind of material that is selected from binding agent and hook and annular holder.
- 18. the therapy system of claim 14 definition, wherein this maintenance and supporting element also are defined as by thermoplastic elastic material and form.
- 19. the therapy system of claim 18 definition, wherein this thermoplastic elastic material is defined as and comprises a kind of following material that is selected from: polyurethane, polyolefin, polybutene, polyethylene, polyester, ethylene propylene rubber, polypropylene, silicone and vinylite.
- 20. the therapy system of claim 17 definition, wherein this fixture is defined as and comprises at least two and be fixed on the apparent surface of this maintenances and supporting element and be positioned at the appropriate location that matches each other, cooperate, be bonded with each other will keep and supporting element remains on any target location of individuality or cooperation, the blocking element at position safely.
- 21. the therapy system of claim 20 definition, wherein this cooperation, blocking element comprise hook and annular fixture to also being defined as, wherein this first pair of blocking element be installed in keep and the first surface of supporting element and with the heat production liner interval of wherein installing, the connection of cooperating; And second interlocking hook and the annular retaining element is fixed on the reverse side of whole basically maintenance and supporting element safely, and what any actually thus target area and position obtained quickly and easily that cooperation, the locking of this first and second blocking element install is bonded with each other.
- 22. the therapy system of claim 17 definition, wherein this erecting device also is defined as and comprises and the heat production liner connects adhesive phase with a surface that is fixed on this maintenance and supporting element of realizing fixture, thereby safely maintenance and supporting element and heat production liner is fixed on any target location or the position of individual's skin.
- 23. the therapy system of claim 17 definition, wherein this heat production liner also is defined as by contacting with oxygen and activates, and this therapy system also be defined as be packaged in oxygen-free, peripheral around releasable container in, to use by this delivery system is stored in make single heat production liner can make short-term in the releasable container when not using recyclingly.
- 24. the therapy system of claim 14 definition, wherein this film former also is defined as and comprises a kind of following material that is selected from: the mixed polymer of polyvinyl acetate, vinyl acetate and acrylic acid mixed polymer, acrylic acid and acrylate, polyvinyl acetate, polyethylene butyryl, polyvinyl alcohol, cellulose derivative, the poly-O-phthalic acid cellulose of acetic acid, cellulose acetate-butyrate, cellulose-acetate propionate, celluloid, sulfate cellulose, ethyl cellulose and cellulose acetate.
- 25. the therapy system of claim 24 definition, wherein this plasticizer also is defined as and comprises at least a following material that is selected from: glyceryl triacetate, polyhydric alcohol, propylene glycol, butanediol, Oleum Ricini, Camphora and phthalic acid ester.
- 26. the therapy system of claim 25, wherein this solvent/volatile vehicle comprises at least a following material that is selected from: alcohol, ethanol, ketone, acetone ether, chloroform, aromatic hydrocarbons, toluene, ester, ethyl acetate and water.
- 27. the therapy system of claim 26 definition, wherein this therapeutic agent comprises one or more and is selected from following material: corticosteroid, chemotherapeutant, anesthetis, hydryllin, anti-infective, antifungal, antibacterial, antiparasitic, antiviral agent, antioxidant, tar, dithranol, immunomodulator, keratolytic and antitumor agent.
- 28. the therapy system of claim 14 definition, wherein this film-forming composition also includes the reinforcing agent that helps the delivery treatments material.
- 29. the therapy system of claim 28 definition, wherein this reinforcing agent comprises one or more and is selected from following material: solvent, surfactant, ether, ester, fatty glyceride, carbamide, oleate, liposome, biostearin and closing compound.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26043001P | 2001-01-09 | 2001-01-09 | |
| US60/260,430 | 2001-01-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1514706A true CN1514706A (en) | 2004-07-21 |
| CN1281287C CN1281287C (en) | 2006-10-25 |
Family
ID=22989129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028035100A Expired - Fee Related CN1281287C (en) | 2001-01-09 | 2002-01-07 | Therapeutic film forming composition and treatment system |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1357873A4 (en) |
| JP (1) | JP2004520337A (en) |
| KR (1) | KR20030072592A (en) |
| CN (1) | CN1281287C (en) |
| AU (1) | AU2002248308B2 (en) |
| BR (1) | BR0206307A (en) |
| CA (1) | CA2431236A1 (en) |
| HU (1) | HUP0501023A3 (en) |
| IL (1) | IL156458A0 (en) |
| NO (1) | NO20033123L (en) |
| NZ (1) | NZ526806A (en) |
| PL (1) | PL362920A1 (en) |
| WO (1) | WO2002055023A2 (en) |
| ZA (1) | ZA200305125B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602697A (en) * | 2012-09-05 | 2015-05-06 | 普索莱尔西斯克利姆瑞典公司 | Composition for treating psoriasis |
| CN104661655A (en) * | 2012-07-23 | 2015-05-27 | 陶氏环球技术有限责任公司 | Film composition for hard capsule shells |
| CN104771781A (en) * | 2014-08-20 | 2015-07-15 | 江阴市柏御天谷生物医药有限公司 | Liquid wound protection film and preparation method thereof |
| CN105999393A (en) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药（福建）有限公司 | Liquid band-aid and preparation method thereof |
| CN108785739A (en) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | A kind of full-service fluid adhesive bandage and preparation method thereof |
| CN109044880A (en) * | 2011-12-14 | 2018-12-21 | 雅芳产品公司 | The cosmetic composition that long-acting easy cleaning is fallen |
| CN110859989A (en) * | 2019-10-25 | 2020-03-06 | 天津冠勤医药科技有限公司 | Liquid band-aid and preparation method thereof |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8741332B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
| JP4863437B2 (en) * | 2005-07-07 | 2012-01-25 | 有限会社日本健康科学研究センター | Bath film formulation |
| AU2006326388B2 (en) * | 2005-12-14 | 2013-01-24 | Nuvo Research Inc. | Compositions and methods for treating dermatological conditions |
| JP5137175B2 (en) * | 2006-10-24 | 2013-02-06 | 有限会社日本健康科学研究センター | Film guard formulation |
| EP1958613A1 (en) * | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| FR2937250B1 (en) * | 2008-10-21 | 2013-05-10 | Fabre Pierre Dermo Cosmetique | UREA-BASED FILMOGENOUS SOLUTION FOR THE TREATMENT OF NAIL PSORASIS |
| JP6596432B2 (en) * | 2014-01-20 | 2019-10-23 | メリアル インコーポレイテッド | Topical delivery formulation |
| CN107320766A (en) * | 2016-12-08 | 2017-11-07 | 沈阳圣劳伦斯医疗器械有限公司 | A kind of composition for skin superficial protecting wound surface |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612305A1 (en) * | 1986-04-11 | 1987-10-22 | Roehm Pharma Gmbh | LIQUID MEDICINE FOR THERAPY OF PSORIASIS BASED ON FILM-FORMING POLYMERS |
| DE4212105A1 (en) * | 1992-04-10 | 1993-10-14 | Roehm Pharma Gmbh | Nail polish for the treatment of onychomycoses |
| US5534021A (en) * | 1994-09-01 | 1996-07-09 | Dvoretzky; Israel | Heating pad for providing heat therapy |
| DE69619111T2 (en) * | 1995-06-29 | 2002-10-31 | The Procter & Gamble Company, Cincinnati | HEAT CELLS |
| RO118174B1 (en) * | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Nail polish and use thereof |
-
2002
- 2002-01-07 EP EP02717290A patent/EP1357873A4/en not_active Withdrawn
- 2002-01-07 BR BR0206307-7A patent/BR0206307A/en not_active IP Right Cessation
- 2002-01-07 AU AU2002248308A patent/AU2002248308B2/en not_active Ceased
- 2002-01-07 HU HU0501023A patent/HUP0501023A3/en unknown
- 2002-01-07 NZ NZ526806A patent/NZ526806A/en unknown
- 2002-01-07 IL IL15645802A patent/IL156458A0/en not_active IP Right Cessation
- 2002-01-07 PL PL02362920A patent/PL362920A1/en unknown
- 2002-01-07 JP JP2002555760A patent/JP2004520337A/en active Pending
- 2002-01-07 CN CNB028035100A patent/CN1281287C/en not_active Expired - Fee Related
- 2002-01-07 KR KR10-2003-7009178A patent/KR20030072592A/en not_active Application Discontinuation
- 2002-01-07 CA CA002431236A patent/CA2431236A1/en not_active Abandoned
- 2002-01-07 WO PCT/US2002/000282 patent/WO2002055023A2/en active Application Filing
-
2003
- 2003-07-01 ZA ZA200305125A patent/ZA200305125B/en unknown
- 2003-07-08 NO NO20033123A patent/NO20033123L/en not_active Application Discontinuation
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109044880A (en) * | 2011-12-14 | 2018-12-21 | 雅芳产品公司 | The cosmetic composition that long-acting easy cleaning is fallen |
| CN104661655A (en) * | 2012-07-23 | 2015-05-27 | 陶氏环球技术有限责任公司 | Film composition for hard capsule shells |
| CN104602697A (en) * | 2012-09-05 | 2015-05-06 | 普索莱尔西斯克利姆瑞典公司 | Composition for treating psoriasis |
| CN104771781A (en) * | 2014-08-20 | 2015-07-15 | 江阴市柏御天谷生物医药有限公司 | Liquid wound protection film and preparation method thereof |
| CN105999393A (en) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药（福建）有限公司 | Liquid band-aid and preparation method thereof |
| CN108785739A (en) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | A kind of full-service fluid adhesive bandage and preparation method thereof |
| CN110859989A (en) * | 2019-10-25 | 2020-03-06 | 天津冠勤医药科技有限公司 | Liquid band-aid and preparation method thereof |
| CN111166932A (en) * | 2020-02-29 | 2020-05-19 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
| CN111166932B (en) * | 2020-02-29 | 2021-01-26 | 海南妙音春制药有限公司 | Liquid wound spray dressing and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002248308B2 (en) | 2006-12-07 |
| KR20030072592A (en) | 2003-09-15 |
| PL362920A1 (en) | 2004-11-02 |
| EP1357873A2 (en) | 2003-11-05 |
| ZA200305125B (en) | 2004-10-01 |
| CN1281287C (en) | 2006-10-25 |
| NO20033123D0 (en) | 2003-07-08 |
| IL156458A0 (en) | 2004-01-04 |
| BR0206307A (en) | 2004-07-20 |
| HUP0501023A3 (en) | 2008-04-28 |
| JP2004520337A (en) | 2004-07-08 |
| CA2431236A1 (en) | 2002-07-18 |
| HUP0501023A2 (en) | 2007-02-28 |
| WO2002055023A2 (en) | 2002-07-18 |
| EP1357873A4 (en) | 2009-09-09 |
| NZ526806A (en) | 2006-03-31 |
| NO20033123L (en) | 2003-09-03 |
| WO2002055023A3 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1281287C (en) | Therapeutic film forming composition and treatment system | |
| RU2349315C9 (en) | Therapeutical plaster with polysiloxane matrix containing capsaicin | |
| CN1578681A (en) | Plaster having laminated support | |
| CN101056611A (en) | Gilsonite derived pharmaceutical delivery compositions and methods : cosmetic and nail applications | |
| MXPA02008828A (en) | Intradermal-penetration agents for topical local anesthetic administration. | |
| CN1298326C (en) | Transdermal patch for external use comprising fentanyl | |
| CN1231592A (en) | Fatty acid esters of glycolic and its salts as permeation enhancers | |
| US20150196515A1 (en) | Multi-Layer Drug Delivery System | |
| CN1531430A (en) | Local used composition containing antifungal agent | |
| SI20360A (en) | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | |
| CN1846792A (en) | Transdermal plaster | |
| CN1747724A (en) | Transdermal granisetron | |
| US20080102108A1 (en) | Therapeutic film forming composition and treatment system therefor | |
| RU2000123787A (en) | SUBSTITUTED 2-PHENYL-1- (3,4-DIHYDROXI-5-NITROPHENYL) HEADRAILOPAHEADOUSOUSOUSOXY-THERMAL CLEANING SYSTEMS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM AND PHARMACEUTICAL HEATING SYSTEM AND PHARMACEUTICAL SYSTEMS AND PHARMACEUTICAL SYSTEMS | |
| KR20100126830A (en) | Transdermally absorbable preparation | |
| CN1364078A (en) | Stretchable patch | |
| AU2002248308A1 (en) | Therapeutic film forming composition and treatment system | |
| CN1154484C (en) | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage | |
| WO2019135123A1 (en) | Liquid dosage form for topical application | |
| CN1153571C (en) | External therapeutic composition for dermatitis | |
| CN1316965C (en) | Transparent disappearing external administration carrier | |
| WO2012105625A1 (en) | Transdermal absorption-promoting agent and transdermal patch containing same | |
| CN101080219A (en) | External patches containing etofenamate | |
| CN1195503C (en) | Transdermal patch and topical compositions comprising propylnorapomorphine | |
| IE912577A1 (en) | Self-sticking matrix system for the sustained transcutaneous¹release of piribedil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |